


**Annex 6-7**



## Annex 6-8

	1999			1998			1997			1996			1995												
	Total of enterovirus positive	Total of polioviruses			Total of enterovirus positive	Total of polioviruses			Total of enterovirus positive	Total of polioviruses			Total of enterovirus positive	Total of polioviruses											
		NT	1	2		3	NT	1		2	3	NT		1	2	3	NT	1	2	3					
Hokkaido	14	0	0	0	0	0	0	0	10	0	0	0	0	4	0	0	0	0	24	0	0	0	0		
Aomori	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Iwate	43	0	3	3	1	59	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Miyagi	22	0	0	0	0	9	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	
Akita	0	0	0	0	0	36	0	0	0	0	0	0	0	75	0	0	0	0	15	0	0	0	0	0	
Yamagata	20	0	0	0	0	51	0	0	0	0	27	0	0	0	0	0	0	0	18	0	0	0	0	0	
Fukushima	129	0	11	22	9	226	0	3	12	8	327	0	4	4	2	77	0	6	7	8	179	0	7	7	2
Ibaragi	29	0	0	0	0	59	0	0	0	0	0	0	0	4	0	0	0	0	6	0	0	0	0	0	
Tochigi	22	0	0	0	0	33	0	0	0	0	7	0	0	0	0	0	0	0	14	0	0	0	1	0	
Gunma	23	0	0	1	0	187	0	1	2	1	46	0	1	4	1	23	0	1	0	0	65	0	2	0	0
Saitama	22	0	0	0	0	127	0	0	0	0	28	0	0	1	0	10	0	0	14	0	0	0	0	0	
Chiba	3	0	0	0	0	50	0	0	0	0	13	0	0	1	0	33	0	0	39	0	0	0	0	0	
Tokyo	64	0	1	0	0	203	0	2	5	0	16	0	2	22	2	7	0	0	6	0	0	0	0	0	
Kanagawa	65	0	1	0	0	371	0	0	1	1	71	0	1	1	3	132	0	4	0	0	123	0	1	3	0

20000540

以降 P.165 は雑誌に掲載された論文となりますので、下記の「資料」をご参照ください。

「資料」

**Virus survey in environmental waters in Miyagi Prefecture.**

Akiyama K, Ueki Y, Okimura Y, Goto I, Noike M, Shiraishi H, Yoneyama T.  
Jpn J Infect Dis. 1999 Aug;52(4):179.

## Annex 6-10

	Toyama	Hiroshima	Miyagi
Population	1,120,000	2,900,000	2,400,000
	river water	sea water (Hiroshima-Bay)	river water sea water
	2 times / month	monthly	monthly
	cotton pads into river for 2 days ↓ 700~800 ml squeezed water	20 l	20 l
Concentration method	membrane filter	membrane filter	DEAF cellulose or membrane filter
Cell used for isolation	VERO, RD-18S MA 104, MK	BGM, Hep2 RD-18S, HeLa	BGM, HeLa Hep2, RD, VERO

	Toyama			Hiroshima			Miyagi		
	No examined	EV	Polio	No examined	EV	Polio	No examined	EV	Polio
1990				22	2	0			
1991				55	2	0			
1992				39	0	0			
1992				18	3	0			
1993 (Oct. ~)		5	1 (P2)						
1994		16	3 (P2,P3,P3)				4	0	0
1995 (~Sep.)		2	2 (P2,P3)				18	0	0
1996							41	0	0
1997							42	1	1 (P3)
1998							27	0	0
1999 (1~3)							6	0	0

— All polio isolated were Sabin-type —

## **Annex 7-1**

# **ORGANIZATION OF NIID**

*DIRECTOR-GENERAL*

*DEPUTY DIRECTOR-GENERAL*

*OFFICE OF ADMINISTRATION*

*PLANNING AND COORDINATION*

*RESEARCH PROMOTION*

*DEPARTMENT OF VIROLOGY I*

*DEPARTMENT OF VIROLOGY II*

*DEPARTMENT OF BACTERIOLOGY*

*DEPARTMENT OF ORAL SCIENCE*

*DEPARTMENT OF PARASITOLOGY*

*DEPARTMENT OF PATHOLOGY*

*DEPARTMENT OF IMMUNOLOGY*

*DEPARTMENT OF BIOACTIVE MOLECULES*

*DEPARTMENT OF BIOCHEMISTRY AND CELL BIOLOGY*

*DEPARTMENT OF BIOMEDICAL FOOD RESEARCH*

*DEPARTMENT OF MEDICAL ENTOMOLOGY*

*DEPARTMENT OF VETERINARY SCIENCE*

*DEPARTMENT OF SAFETY RESEARCH ON BIOLOGICS\**

*DEPARTMENT OF VIRAL DISEASE AND VACCINE CONTROL\**

*DEPARTMENT OF BACTERIAL AND BLOOD PRODUCTS\**

*DIVISION OF INTERNATIONAL COOPERATION*

*DIVISION OF MOLECULAR GENETICS*

*DIVISION OF GENETIC RESOURCES*

*DIVISION OF BIOSAFETY CONTROL AND RESEARCH*

*DIVISION OF RADIOLOGICAL PROTECTION AND BIOLOGY*

*DIVISION OF EXPERIMENTAL ANIMALS RESEARCH*

*INFECTIOUS DISEASE SURVEILLANCE CENTER*

*AIDS RESEARCH CENTER*

*LIBRARY*

*MURAYAMA BRANCH\**

*TSUKUBA PRIMATE CENTER FOR MEDICAL SCIENCE*

*LEPROSY RESEARCH CENTER*

The departments marked with \* are in Musashimurayama Branch.

## Annex 7-2

### CHARACTERIZATION OF POLIOVIRUS ISOLATES IN 1993

CODE	AGE&SEX	DATE OF VACCINATION	DATE OF ONSET (SAMPLING)	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DIFFERENTIATION	RT/40 MARKER	REMARKS
SHIGA 93-1	13Y MALE	OCT.3,1980	JAN.19,1993 (JAN.22,1993)	U.R.D.	POLIO-3	NON-VACCINE-LIKE	-	TH.SWAB
HOKKAIDO 93-1	1Y6M MALE	NONE	JUN.16,1993 (JUN.28,1993)	PARALYSIS	POLIO-2	VACCINE-LIKE	±	FECES
OSAKA 93-1	9M MALE	OCT.1,1991	OCT.17,1991 (OCT.25,1991)	PARALYSIS	POLIO-2 POLIO-3	VACCINE-LIKE VACCINE-LIKE	- +	FECES FECES
FUKUOKA 93-1	19Y MALE	UNKNOWN	JUL.11,1993 (AUG.26,1993)	PARALYSIS	POLIO-3	VACCINE-LIKE	-	FECES
OITA 93-1	9M MALE	NONE	AUG.9,1993 (AUG.10,1993)	PARALYSIS	POLIO-2	VACCINE-LIKE	±	CSF
KANAGAWA 93-1	4M MALE	SEP.29,1992	OCT.26,1992 (OCT.27,1992)	PARALYSIS	POLIO-3	VACCINE-LIKE	±	FECES

### CHARACTERIZATION OF POLIOVIRUS ISOLATES IN 1994

CODE	AGE&SEX	DATE OF VACCINATION	DATE OF ONSET (SAMPLING)	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DIFFERENTIATION	REMARKS
HIROSHIMA 94-1	7M FEMALE	UNCLEAR	(94-4-19)	*BELL'S PALSY	POLIO-1 POLIO-2 POLIO-3	VACCINE-LIKE VACCINE-LIKE VACCINE-LIKE	TH.SWAB URINE STOOL
HIROSHIMA 94-4	5M MALE	UNCLEAR	(94-4-30)	INSUFFICIENCY OF LIVER FUNCTION	POLIO-1	VACCINE-LIKE	STOOL
HIROSHIMA 94-5	9M FEMALE	94-2-1	(94-11-11)	PNEUMONIA	POLIO-2 POLIO-3	VACCINE-LIKE VACCINE-LIKE	TH.SWAB STOOL
HIROSHIMA 94-7	10M MALE	UNCLEAR	(94-11-20)	DIARRHEA	POLIO-3	VACCINE-LIKE	STOOL
FUKUOKA 94-1	1Y MALE	94-1-21(2nd)	94-2-7 (94-2-11)	**G.B.S.	POLIO-3	VACCINE-LIKE	STOOL
SHIZUOKA 94-1	3M MALE	NONE	94-11-3 (94-11-6)	MYOCARDITIS	POLIO-1 POLIO-2	VACCINE-LIKE VACCINE-LIKE	TH.SWAB TH.SWAB
HOKKAIDO 94-1	7M MALE	94-10-19	(94-11-2)	***U.R.D.	POLIO-2	VACCINE-LIKE	TH.SWAB
TOTTORI 94-1	2Y MALE	92-10-20	93-12-28 (93-12-29)	U.R.D.	POLIO-1 POLIO-2	VACCINE-LIKE VACCINE-LIKE	TH.SWAB TH.SWAB
KUMAMOTO 94-1	6M MALE	94-4-6	94-4-28 (94-5-13)	PARALYSIS	POLIO-1	VACCINE-LIKE	STOOL
NAGASAKI 94-1	9M FEMALE	85-10-19	94-8-18 (94-8-21)	STOMATITIS	POLIO-2	VACCINE-LIKE	TH.SWAB

### CHARACTERIZATION OF POLIOVIRUS ISOLATES IN 1995

CODE	AGE & SEX	DATE OF VACCINATION	DATE OF ONSET (SAMPLING)	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DEFERENTIATION	REMARKS
WAKAYAMA 95-1	1Y MALE	94-4-26	(95-4-28)	GASTROENTERITIS	POLIO-1	VACCINE-LIKE	STOOL
WAKAYAMA 95-2	1Y FEMALE	94-12-1	(95-5-6)	GASTROENTERITIS	POLIO-1	VACCINE-LIKE	TH.SWAB
GIFU 96-1	1Y MALE	95-5-18	95-6-5 (95-6-6)	HERPANGINA	POLIO-3	VACCINE-LIKE	TH.SWAB
GIFU 96-2	3Y FEMALE	93-10	95-6-7 (95-6-8)	UNCLEAR	POLIO-3	VACCINE-LIKE	TH.SWAB
EHUME 96-1	11M MALE	NONE	(95-9-6)	HEALTHY	POLIO-2	VACCINE-LIKE	STOOL

CHARACTERIZATION OF POLIOVIRUS ISOLATES IN 1996

CODE	AGE	SEX	DATE OF VACCINATION	DATE OF ONSET	DATE OF SAMPLING	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DIFFERENTIATION	REMARKS
96-SHIGA-1	2Y	M	NONE	96-4-22	96-4-23	U.R.I.	POLIO-2	VACCINE-LIKE	
96-FUKUSHIMA-1	7M	M	NONE	96-5-4	96-5-8	PNEUMONIA	POLIO-1	VACCINE-LIKE	
96-Mie-1	1Y	F	95-6	95-11-27	95-11-28	DIARRHEA	POLIO-1	VACCINE-LIKE	
96-Mie-3	4M	F	NONE	96-1-10	96-1-17	FEBRILE ILLNESS	POLIO-3	VACCINE-LIKE	
96-Mie-4	1Y	F	95-11	96-2-26	96-2-26	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-5	3Y	M	93-6		96-5-10	HEALTHY	POLIO-3	VACCINE-LIKE	
96-Mie-6	4Y	F	93-6	96-5-9	96-5-10	FEBRILE ILLNESS	POLIO-3	VACCINE-LIKE	Food-borne gastroenteritis
96-Mie-7	3Y	F	93-6		96-5-10	HEALTHY	POLIO-3	VACCINE-LIKE	
96-Mie-8	3Y	M	93-11	96-5-8	96-5-10	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-9	2Y	M	94-11		96-5-10	HEALTHY	POLIO-3	VACCINE-LIKE	
96-Mie-10	1Y	M	96-5-8	96-5-26	96-6-5	G.B.S.	POLIO-3	VACCINE-LIKE	
96-Mie-11	10M	F	95-11		96-6-21	HEART-FAILURE	POLIO-3	VACCINE-LIKE	
96-Mie-12	10Y	M	85-6	96-7-11	96-7-13	DIARRHEA	POLIO-3	VACCINE-LIKE	Food-borne gastroenteritis
96-Mie-13	52Y	F	NONE		96-7-13	HEALTHY	POLIO-3	VACCINE-LIKE	
96-Mie-14	10Y	M	87-6	96-7-12	96-7-13	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-15	10Y	F	87-6	96-7-11	96-7-14	HEALTHY	POLIO-3	VACCINE-LIKE	
96-Mie-16	10Y	F	87-6	96-7-12	96-7-14	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-17	11Y	M	84-11	96-7-10	96-7-14	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-18	8Y	F	89-6		96-7-14	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-19	9Y	M	87-11		96-7-15	HEALTHY	POLIO-3	VACCINE-LIKE	
96-Mie-20	11Y	M	85-11	96-7-10	96-7-18	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-21	11Y	M	85-11	96-7-11	96-7-18	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-22	6Y	F	90-11	96-7-26	96-7-29	ASEPTIC MENINGITIS	POLIO-1	VACCINE-LIKE	
96-Mie-23	3Y	F	93-11	96-8-12	96-8-14	DIARRHEA	POLIO-1	VACCINE-LIKE	
96-Mie-24	42Y	F	NONE	96-8-26	96-8-28	DIARRHEA	POLIO-3	VACCINE-LIKE	Food-borne gastroenteritis
96-Mie-25	7Y	M	90-6	96-8-26	96-8-26	DIARRHEA	POLIO-3	VACCINE-LIKE	
96-Mie-26	10Y	M	86-11	96-8-25	96-8-26	DIARRHEA	POLIO-1	VACCINE-LIKE	
96-Mie-29	24Y	F	73-6	96-8-26	96-8-27	DIARRHEA	POLIO-1	VACCINE-LIKE	
96-Mie-30	9Y	F	87-11	96-8-24	96-8-26	DIARRHEA	POLIO-1	VACCINE-LIKE	
96-Mie-31	10Y	F	UNKOWN	96-9-6	96-9-12	FEBRILE ILLNESS	POLIO-1	VACCINE-LIKE	
96-Mie-32	10Y	F	UNKOWN	96-9-22	96-9-30	DIARRHEA	POLIO-1	VACCINE-LIKE	
97-AICHI-3	1Y	F	NONE		96-9-10	HEALTHY	POLIO-2	VACCINE-LIKE	
97-MIYAGI-1	1Y	F	96-11-8		97-1-29	HEALTHY	POLIO-2	VACCINE-LIKE	

Characterization of poliovirus isolates in 1997

CODE	AGE	SEX	DATE OF VACCINATION	DATE OF ONSET	DATE OF SAMPLING	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DIFFERENTIATION	REMARKS
97-WAKAYAMA-1	1Y	F	96-4-16	96-5-1	96-5-2	CEREBRAL INFARCTION	POLIO-3	VACCINE-LIKE	
97-OSAKA-1	1Y	M	NONE	96-11-24	96-11-27	DIARRHEA	POLIO-2	VACCINE-LIKE	
97-OKAYAMA-1	12Y	M	UNKOWN	96-10-19	96-10-19	ENCEPHALOMYELITIS	POLIO-1	VACCINE-LIKE	
97-KYOTO-1	10M	F	96-11-28	96-12-15	96-12-16	U.R.D.*	POLIO-2	VACCINE-LIKE	
97-AICHI-1	1Y	M	NONE	96-7-29	96-7-29	PNEUMONIA	POLIO-1&3	VACCINE-LIKE	
97-AICHI-2	11M		96-1-26	96-7-27	96-7-29	PNEUMONIA	POLIO-3	VACCINE-LIKE	
97-AICHI-4	21Y	F	97-4-8		97-4-11	U.R.D.	POLIO-1	VACCINE-LIKE	
97-AICHI-5-6	20Y	F	97-4-8		97-4-11	U.R.D.	POLIO-1	VACCINE-LIKE	
97-KOBE-1	10M	F	NONE		95-11-18	DIARRHEA	POLIO-2	VACCINE-LIKE	
97-KOBE-2	11M	M	NONE	96-11-11	96-11-14	DIARRHEA	POLIO-3	VACCINE-LIKE	
97-KOBE-3	1Y	F	95-11	96-11-15	96-11-16	DIARRHEA	POLIO-3	VACCINE-LIKE	
97-OHITA-1	1Y	M	NONE	97-4-8	97-4-18	PNEUMONIA	POLIO-2	VACCINE-LIKE	
97-KYOTO-2	1Y	F	97-5-16	97-5-22	97-5-29	TRANSIENT PARALYSIS	POLIO-1&2	VACCINE-LIKE	
97-KYOTO-3	3M	F	97-5-21	97-5-13	97-5-26	DIARRHEA	POLIO-1&2	VACCINE-LIKE	
97-KUMAMOTO-1	1Y	M	97-5-29	97-6-9	97-6-16	TRANSIENT PARALYSIS	POLIO-1	VACCINE-LIKE	
97-NAGAYASI-1	9M	F	97-4-16	97-5-13	97-5-13	TRANSIENT PARALYSIS	POLIO-1	VACCINE-LIKE	
97-SHIMANE-1	1Y	M	NONE	97-9-16	97-9-17	U.R.D.	POLIO-2	VACCINE-LIKE	
97-SHIGA-1	10M	M	97-11-20	97-12-8	97-12-18	G.B.S. §	POLIO-2	VACCINE-LIKE	
98-FUKUOKA-1	1Y	M	97-9-29	97-10-7	97-10-7	ENCEPHALITIS	POLIO-3	VACCINE-LIKE	
98-FUKUOKA-2	1Y	F	97-10-22	97-11-21	97-11-25	FACIAL PALSY	POLIO-2	VACCINE-LIKE	
98-TOKYO-1	4Y	M	95-7-14		97-8-27	HEALTHY	POLIO-2	VACCINE-LIKE	
98-TOKYO-2	8M	M	97-5-1		97-7-17	HEALTHY	POLIO-2	VACCINE-LIKE	
98-TOKYO-3	8M	F	97-5-1		97-7-17	HEALTHY	POLIO-1&2	VACCINE-LIKE	
98-TOKYO-4	8M	M	97-5-1		97-7-23	HEALTHY	POLIO-1&2	VACCINE-LIKE	
98-TOKYO-5	7M	F	NONE		97-7-27	HEALTHY	POLIO-1&2	VACCINE-LIKE	
98-TOKYO-6	2Y	M	96-10-25		97-7-22	HEALTHY	POLIO-1&2	VACCINE-LIKE	
98-TOKYO-7	2Y	M	96-5-16		97-7-23	HEALTHY	POLIO-2	VACCINE-LIKE	
98-TOKYO-8	4Y	M	94-4-25		97-7-17	HEALTHY	POLIO-2	VACCINE-LIKE	
98-TOKYO-9	10Y	F	UNKOWN	97-10-7	97-10-10	ASEPTIC MENINGITIS	POLIO-2	VACCINE-LIKE	
98-TOKYO-10-11	5Y	F	UNKOWN	97-10-1	97-10-14	ENCEPHALOMYELITIS	POLIO-2	VACCINE-LIKE	
98-TOKYO-12	1Y	F	97-9-24	97-11-10	97-11-23	PNEUMONIA	POLIO-3	VACCINE-LIKE	
98-MIE-1	1Y	F	97-9-24	97-9-26	97-10-1	U.R.D.	POLIO-3	VACCINE-LIKE	
98-MIE-2	8M	M	97-4-15		97-7-1	HEALTHY	POLIO-2	VACCINE-LIKE	
98-MIE-3	8M	F	97-5-20		97-7-21	HEALTHY	POLIO-2	VACCINE-LIKE	
98-MIE-4	8M	M	97-5-20		97-7-29	HEALTHY	POLIO-2	VACCINE-LIKE	
98-MIE-5	8M	F	97-5-30		97-8-1	HEALTHY	POLIO-3	VACCINE-LIKE	
98-MIE-6	8M	M	97-5-30		97-8-7	HEALTHY	POLIO-1	VACCINE-LIKE	
98-MIE-7	1Y	F	97-5-20		97-8-8	HEALTHY	POLIO-3	VACCINE-LIKE	

\* Upper Respiratory Disease

§ Guillain-Barre Syndrome



## CHARACTERIZATION OF POLIOVIRUS ISOLATES IN 1998

CODE	AGE	SEX	DATE OF VACCINATION	DATE OF ONSET	DATE OF SAMPLING	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DIFFERENTIATION	REMARKS
98-KYOTO-1	1Y	F	1998-4-10	98-4-12	98-4-14	DIARRHEA	POLIO-3	VACCINE-LIKE	
98-NARA-1	4M	F	1998-5-18	98-5-25	98-5-28	ENCEPHALITIS	POLIO-1	VACCINE-LIKE	
98-SHIGA-2	7M	M	NONE	98-5-13	98-5-28	U.R.D.	POLIO-2	VACCINE-LIKE	
98-NAGOYA-1	1Y	M	1998-4-7	98-4-11	98-4-14	TRANSIENT PARALYSIS	POLIO-2	VACCINE-LIKE	
98-KYOTO-2	1Y	F	UNKNOWN	98-5-21	98-5-22	U.R.D.	POLIO-1	VACCINE-LIKE	
98-MIE-8	2M	M	NONE	98-2-15	98-4-24	ASEPTIC MENINGITIS	POLIO-2	VACCINE-LIKE	
98-HOKKAIDO-1	36Y	M	UNKNOWN	98-6-1	98-6-15	POLIOMYELITIS	POLIO-1	VACCINE-LIKE	
98-HOKKAIDO-2	9M	F	98-5-18		98-6-15	HEALTHY	POLIO-1&2	VACCINE-LIKE	
98-NIIGATA-1	13Y	M	UNKNOWN	98-1-24	98-1-25	FEVER	POLIO-1	VACCINE-LIKE	TH.S
98-NIIGATA-2	9Y	M	UNKNOWN	98-1-29	98-1-29	FEVER	POLIO-1	VACCINE-LIKE	TH.S
99-KYOTO-1	2Y	M	98-10-28(2ND)	98-11-8	98-11-19	POLIOMYELITIS	POLIO-3	VACCINE-LIKE	

## CHARACTERIZATION OF POLIOVIRUS ISOLATES IN 1999

CODE	AGE	SEX	DATE OF VACCINATION	DATE OF ONSET	DATE OF SAMPLING	CLINICAL INFORMATION	SEROTYPE	INTRATYPIC DIFFERENTIATION
99-KYOTO-2	7M	F	98-4-16	98-5-2	98-5-2	ASEPTIC MENINGITIS	POLIO-2	VACCINE-LIKE
99-NIIGATA-1	1Y	F	98-10-23	99-4-5	99-4-9	GASTROENTERITIS	POLIO-1 & 2	VACCINE-LIKE
99-NIIGATA-2	2Y	M	98-11-2	UNKOWN	99-4-12	ERYTHEMA INFECTIOSUM	POLIO-1	VACCINE-LIKE
99-FUKUSHIMA-1	5Y	M	UNKOWN	99-2-17	99-2-17	*URD	POLIO-1	VACCINE-LIKE
99-FUKUSHIMA-2	7M	M	UNKOWN	99-4-30	99-4-30	**ITP	POLIO-2	VACCINE-LIKE
99-NIIGATA-3	3Y	F	97-5-9(2nd)	99-5-31	99-5-31	URD	POLIO-1	VACCINE-LIKE
99-NIIGATA-4	7Y	F	UNKOWN	99-6-24	99-6-25	HERPANGINA	POLIO-1	VACCINE-LIKE
99-NARA-1	8M	F	NONE	99-11-24	99-11-24	DIARRHEA	POLIO-2&3	VACCINE-LIKE
00-AICHI-1	1Y	F	99-6-21		99-10-12	HEALTHY	POLIO-2	VACCINE-LIKE
00-FUKUOKA-1	6M	F	99-11-2	99-12-1	99-12-9	DIARRHEA	POLIO-1	VACCINE-LIKE
00-TOYAMA-1	7M	F	99-9-13		99-12-17	HEALTHY	POLIO-2	VACCINE-LIKE

\* : UPPER RESPIRATORY DISEASE

\*\* : IDIOPATHIC THROMBOCYTOPENIC PURPURA

20000540

以降は雑誌/図書に掲載された論文となりますので、  
P.253の「研究成果の刊行に関する一覧表」をご参照ください。

## Annex 8-1

Year: 1999

1 <sup>st</sup> Administrative unit	Target population	No. of Doses (i.e. OPV3)	Immunization Coverage (%)
	Standard Immunization (3~90M)	1 <sup>st</sup> round + 2 <sup>nd</sup> round	1 <sup>st</sup> round + 2 <sup>nd</sup> round
Hokkaido	47,975	95,949	100.0
Aomori	16,109	29,880	92.7
Iwate	13,834	24,620	89.0
Miyagi	21,959	43,917	100.0
Akita	9,902	18,798	94.9
Yamagata	11,130	22,260	100.0
Fukushima	26,792	42,436	79.2
Ibaragi	29,010	58,020	100.0
Tochigi	19,236	38,471	100.0
Gunma	19,893	39,309	98.8
Saitama	67,541	135,081	100.0
Chiba	55,208	110,416	100.0
Tokyo	94,972	189,944	100.0
Kanagawa	81,707	163,413	100.0
Niigata	23,874	43,794	91.7
Toyama	11,537	19,684	85.3
Ishikawa	10,781	20,385	94.5
Fukui	8,553	16,445	96.1
Yamanashi	10,047	17,012	84.7
Nagano	21,363	42,726	100.0
Gifu	21,617	43,233	100.0
Shizuoka	36,318	72,636	100.0
Aichi	78,737	145,452	92.4
Mie	20,099	34,983	87.0
Shiga	14,299	28,007	97.9
Kyoto	24,183	48,277	99.8
Osaka	88,007	174,324	99.0
Hyogo	54,864	107,675	98.1

Nara	14,463	28,925	100.0
Wakayama	14,170	19,289	68.1
Tottori	5,426	10,851	100.0
Shimane	6,947	11,596	83.5
Okayama	24,125	37,569	77.9
Hiroshima	26,821	53,642	100.0
Yamaguchi	13,934	26,450	94.9
Tokushima	7,745	13,953	90.1
Kagawa	9,826	19,651	100.0
Ehime	48,867	26,662	70.7
Kochi	7,842	13,308	84.9
Fukuoka	54,199	108,398	100.0
Saga	9,534	17,210	90.3
Nagasaki	14,529	29,057	100.0
Kumamoto	19,003	34,311	90.3
Oita	11,909	21,867	91.8
Miyazaki	11,744	14,015	59.7
Kagoshima	19,842	30,951	78.0
Okinawa	19,614	39,228	100.0
Total	1,250,085	2,384,080	98.8

Year: 2000

1 <sup>st</sup> Administrative unit	Target population	No. of Doses (i.e. OPV3)	Immunization Coverage (%)
	Standard Immunization (3~90M)	1 <sup>st</sup> round	1 <sup>st</sup> round
Hokkaido		19,285	
Aomori		15,496	
Iwate		10,076	
Miyagi		22,879	
Akita		3,502	
Yamagata		4,879	
Fukushima		11,169	
Ibaragi		10,093	
Tochigi		9,841	
Gunma		11,129	
Saitama		37,746	
Chiba		17,340	
Tokyo		53,202	
Kanagawa		70,140	
Niigata		13,212	
Toyama		4,256	
Ishikawa		4,646	
Fukui		6,457	
Yamanashi		3,066	
Nagano		17,925	
Gifu		10,397	
Shizuoka		28,171	
Aichi		50,452	
Mie		8,035	
Shiga		13,521	
Kyoto		17,749	

Osaka		65,533	
Hyogo		26,221	
Nara		11,248	
Wakayama		4,416	
Tottori		1,470	
Shimane		3,140	
Okayama		10,281	
Hiroshima		25,987	
Yamaguchi		7,603	
Tokushima		1,570	
Kagawa		4,982	
Ehime		3,277	
Kochi		1,354	
Fukuoka		33,362	
Saga		2,434	
Nagasaki		10,561	
Kumamoto		13,297	
Oita		12,889	
Miyazaki		6,289	
Kagoshima		5,220	
Okinawa		2,989	
Total		728,787	

## Annex 8-2

### Distribution of polio NT antibody titers by age group

#### Type I

AGE	NT ANTIBODY TITER TO TYPE 1											
	TOTAL	<4	4	8	16	32	64	128	256	256<	G.M.	Log <sub>2</sub> (G.M.)
TOTAL	1597	149	61	86	116	150	193	179	196	467	107.7	6.8
0-1	144	28	1	2	3	1	5	3	7	94	345.1	8.4
2-3	150	5	0	2	2	0	13	13	18	97	309.9	8.3
4-6	169	3	1	1	5	5	10	15	33	96	272.5	8.1
7-9	154	4	4	2	4	6	21	25	39	49	172.0	7.4
10-14	177	5	3	9	13	17	20	24	33	53	125.4	7.0
15-19	182	13	9	11	15	23	26	28	22	35	80.2	6.3
20-24	155	34	9	13	11	30	26	15	4	13	44.1	5.5
25-29	134	26	8	12	21	14	19	14	9	11	43.8	5.5
30-39	156	18	13	12	23	21	22	22	17	8	43.8	5.5
40-	176	13	13	22	19	33	31	20	14	11	40.4	5.3

#### Type II

AGE	NT ANTIBODY TITER TO TYPE 2											
	TOTAL	<4	4	8	16	32	64	128	256	256<	G.M.	Log <sub>2</sub> (G.M.)
TOTAL	1597	42	38	61	126	190	289	299	237	315	97.3	6.6
0-1	144	19	6	3	6	1	5	6	14	84	242.2	7.9
2-3	150	4	1	3	1	3	20	24	31	63	216.8	7.8
4-6	169	1	1	2	3	7	39	45	31	40	148.5	7.2
7-9	154	2	1	3	5	17	41	34	28	23	110.1	6.8
10-14	177	2	1	2	13	31	41	34	26	27	95.1	6.6
15-19	182	3	7	7	21	28	34	33	32	17	71.6	6.2
20-24	155	2	6	5	9	26	35	31	20	21	80.6	6.3
25-29	134	3	5	11	14	20	24	26	19	12	63.7	6.0
30-39	156	1	3	10	19	26	29	30	23	15	68.4	6.1
40-	176	5	7	15	35	31	21	36	13	13	47.8	5.6

#### Type III

AGE	NT ANTIBODY TITER TO TYPE 3											
	TOTAL	<4	4	8	16	32	64	128	256	256<	G.M.	Log <sub>2</sub> (G.M.)
TOTAL	1597	374	163	195	189	203	168	127	75	103	31.8	5.0
0-1	144	65	6	1	9	10	7	16	11	19	90.9	6.5
2-3	150	20	3	8	10	18	30	19	18	23	83.1	6.4
4-6	169	16	6	19	12	35	30	20	13	18	53.4	5.7
7-9	154	42	20	13	22	21	14	12	4	6	25.9	4.7
10-14	177	49	26	29	14	17	14	7	5	16	25.4	4.7
15-19	182	47	24	32	29	22	14	8	5	1	17.6	4.1
20-24	155	48	23	24	23	12	13	2	2	8	18.5	4.2
25-29	134	51	13	18	15	16	9	5	5	2	21.4	4.4
30-39	156	23	21	23	26	29	15	12	4	3	22.0	4.5
40-	176	13	21	28	29	22	22	26	8	7	29.1	4.9

## **Annex 9-1**

I hereby promulgate the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections.

The Imperial Sign and Seal

Keizo Obuchi, Prime Minister

October 2, 1998

Law No. 114

Law Concerning the Prevention of Infections and Medical Care for Patients of Infections

### **Contents**

Preamble

Chapter 1 General Provisions (Articles 1-8)

Chapter 2 Basic Guidelines (Articles 9-11)

Chapter 3 Collection and Publication of Information concerning Infections (Articles 12-16)

Chapter 4 Medical Examination, Restrictions on Employment and Hospitalization (Articles 17-26)

Chapter 5 Disinfecting and Other Measures (Articles 27-36)

Chapter 6 Medical Care (Articles 37-44)

Chapter 7 New Infections (Articles 45-53)

Chapter 8 Measures Concerning Import of Animals that might Transmit the Pathogens of Infectious Diseases (Articles 54-56)

Chapter 9 Share of Cost (Articles 57-63)

Chapter 10 Miscellaneous Provisions (Articles 64-66)

Chapter 11 Punitive Provisions (Articles 67-69)

Supplementary Provisions

To date, human beings have suffered a great deal from diseases, particularly infections. In some cases, the epidemic of infections such as plagues, variola and cholera has driven our civilization to the verge of extinction. To eradicate infections is an earnest wish for mankind.

While a number of infections have been conquered by advanced medicines and remarkably improved sanitation, the emergence of new infections and the recurrence of existing infections are imposing a new form of threat on mankind, as international exchange is promoted.

In Japan, it is important to acknowledge the fact that discrimination and prejudice



against the patients of Hansen's disease or acquired immunodeficiency syndrome (AIDS) existed in the past and to make use of the lessons we learned from these experiences.

Based on the changing situation concerning infections and the circumstances surrounding the patients of infections, we are now required to ensure effective medical treatment for these patients and to deal with infections promptly and appropriately, while respecting the human rights of the patients.

From the above standpoint, this law is hereby enacted in order to drastically reexamine preventive measures against infections and promote comprehensive measures concerning medical care for the patients of infections.

## Chapter 1 General Provisions

### (Purpose)

Article 1 The purpose of this law is to prevent the outbreak and spread of infections by setting out the necessary measures concerning the prevention of infections and medical care for the patients of infections for the ultimate purpose of improving and enhancing public health.

### (Basic Principles)

Article 2 The basic principle of the measures to be taken by the national government and local public entities for the purpose of preventing the outbreak and spread of infections is to respond promptly to the changing situation concerning health and medical care as well as the development of international exchanges, to fully recognize the circumstances surrounding the patients of infections so as to be able to deal with new and other infections promptly and appropriately, and the comprehensive and systematic adoption of these measures while respecting the rights of the patients.

### (Obligations of National and Local Public Entities)

Article 3 The national government and local public entities shall promulgate correct information concerning infections through educational activities and public relations; collect, classify, analyze and distribute information on infections, promote research on infections, improve techniques to test the pathogens of infections, give training for the personnel who are engaged in activities to prevent infections and enhance their abilities, and take necessary measures to provide the patients of infections with effective, high quality treatment. In carrying out these measures, the national government and local public entities shall see to it that the rights of the patients are protected.

- 2 The national government and local public entities shall cooperate with each other so that preventive measures against infections are carried out promptly and comprehensively.
- 3 The national government shall establish a system to collect information on infections, promote research and development of medicines to treat infections and conduct tests of pathogens, while providing the technical and financial support necessary for local public entities to perform their obligations stipulated in the preceding two sections.

(Obligations of the People)

Article 4 The people shall make efforts to obtain correct information concerning infections and take necessary care for the prevention of the spread of infections, while ensuring that the rights of the patients of infections are not violated.

(Obligations of Doctors)

Article 5 Doctors and other medical personnel shall cooperate with the national government and local public entities in implementing preventive measures against infections to contribute to the prevention of infections, and, at the same time, make efforts to provide effective medical care of high quality to the patients of infections based on a comprehensive awareness of the circumstances surrounding them.

- 2 Those who establish or manage hospitals, clinics, facilities for social welfare for the elderly and other medical facilities shall take necessary measures to prevent infections from breaking out and spreading within such facilities.

(Definition)

Article 6 The term "infections" in this law refers to category 1 infections, category 2 infections, category 3 infections, category 4 infections, designated infections and new infections.

- 2 The term "category 1 infections" in this law refers to the Ebola virus, Crimean-Congo haemorrhagic fever, plagues, the Marburg virus disease, and Lassa fever.
- 3 The term "category 2 infections" in this law refers to acute poliomyelitis, cholera, shigellosis, diphtheria, typhoid fever and paratyphoid fever.
- 4 The term "category 3 infections" in this law refers to enterohaemorrhagic Escherichia coli infection.
- 5 The term "category 4 infections" in this law refers to already known infectious diseases designated by the ordinance of the Ministry of Health and Welfare as

diseases which may affect the health of the people including influenza, viral hepatitis, yellow fever, Q fever, rabies, cryptosporidiosis, acquired immunodeficiency syndrome, chlamydial infection of genital tract, syphilis, measles, malaria, methicillin-resistant staphylococcus aureus infection.

- 6 The term "designated infections" in this law refers to already known infectious diseases (excluding category 1, 2 and 3 infections) designated by the ordinance as diseases which may threaten the lives of or seriously affect the health of the people unless all or part of the provisions in Chapter 3 through Chapter 6 are not applied.
- 7 The term "new infections" in this law refers to diseases which are proved to be transmitted from person to person, cause distinctively different symptoms from those of already known infectious diseases, respond differently to the existing treatment and induce serious conditions, an epidemic of which may threaten the lives of or seriously affect the health of the people.
- 8 The term "suspected patient" in this law refers to a person who has symptoms similar to those of an infection.
- 9 The term "pathogen carrier with no symptoms" in this law refers to a person who has the pathogen of an infection but does not develop any of the symptoms of said infection.
- 10 The term "medical institutions designated to treat infections" in this law refers to specified medical institutions designated to treat infections, class 1 medical institutions designated to treat infections and class 2 medical institutions designated to treat infections.
- 11 The term "specified medical institutions designated to treat infections" in this law refers to hospitals designated by the Minister of Health and Welfare as medical institutions which shall admit those who have the symptoms of new infections or the patients of category 1 or category 2 infections.
- 12 The term "class 1 medical institutions designated to treat infections" in this law refers to hospitals designated by the prefectural governor as medical institutions which shall admit the patients of category 1 or category 2 infections.
- 13 The term "class 2 medical institutions designated to treat infections" in this law refers to hospitals designated by the prefectural governor as medical institutions which shall admit the patients of category 2 infections.

(Application of this Law to Designated Infections)

Article 7 With regard to designated infections, all or part of the provisions of the following article, Chapters 3 to 6 and Chapters 8 to 10 shall be applied pursuant to the provisions of the ordinance for the period of not more than one

- (1) year specified by the ordinance.
2. The period specified by the ordinance referred to in the preceding section may be extended for the period of not more than one (1) year specified by the ordinance, provided that the application of the provisions which were applied to the infection specified in the ordinance referred to in the preceding section according to such ordinance is deemed to be necessary after the expiration of said period.
3. The Minister of Health and Welfare shall seek the opinion of the Council on Public Health prior to the enactment, abolishment or amendment of the ordinances referred to in the preceding two sections.

(Application of the Law to Suspected Patients and Pathogen Carriers with No Symptoms)

- Article 8 With regard to suspected patients of category 1 infections and some of category 2 infections specified by the ordinance, the provisions of this law shall be applied as if they were the patients of category 1 infections or category 2 infections accordingly.
2. With regard to the pathogen carriers of category 1 infections with no symptoms, the provisions of this law shall be applied as if they were the patients of category 1 infections.

## Chapter 2 Basic Guidelines

(Basic Guidelines)

- Article 9 The Minister of Health and Welfare shall establish basic guidelines for the comprehensive promotion of preventive measures against infections (hereinafter referred to as "Basic Guidelines").
2. The Basic Guidelines shall set out the matters listed below.
    - (1) Basic direction of the promotion of preventive measures against infections
    - (2) Matters related to measures to prevent the outbreak of infections
    - (3) Matters related to measures to prevent the spread of infections
    - (4) Matters related to the establishment of a framework to provide medical care for infections
    - (5) Matters related to research and study on infections
    - (6) Matters related to the promotion of research and development of medicines to be used in the medical care of infections
    - (7) Matters related to the improvement of the system to test pathogens of infections and its testing capacity
    - (8) Matters related to the training of those who are engaged in activities to